Policy & Guidelines for Working with Private Sector Partners

FIND is a Swiss non-profit foundation, recognized by the Swiss government as an international organization under Swiss UID No. CHE-110.162.567. With headquarters located in Geneva, Switzerland, FIND has offices in India, Uganda, Vietnam and South Africa. Its mission is to turn complex diagnostic challenges into simple solutions to overcome diseases of poverty and transform lives.

To accomplish its mission, FIND has four strategic goals:

I. Catalysing Development
II. Guiding Use and Informing Policy
III. Accelerating Access
IV. Shaping the Agenda

These are described in more detail in FIND’s 2015-2020 strategy.

The purpose of this document is to outline how FIND wishes to work with private sector partners, which includes all entities that are privately owned, or are developing or commercializing products or services for commercial purposes. It addresses the context of transparency, independence, absence of conflicts of interest, and objective standards to which FIND wishes to be held accountable when working with private sector partners.

In order to achieve its strategic goals, FIND works closely with private and public sector entities. FIND is a nongovernmental organization in official relations with the World Health Organization (WHO) and intends to maintain this status in order to be able to continue to provide data on diagnostics that can help to inform public health policies. FIND also needs to find sustainable ways of financing its projects in order to provide essential diagnostics to patients in low- and middle-income countries (LMICs). This requires the ability to enter into flexible partnerships that are compatible with FIND’s core mission and operating policies, such as set out in this document. Such partnerships, especially those with private sector, in vitro diagnostic (IVD) developers and manufacturers, should be transparent and available for review and monitoring by FIND’s independent Scientific Advisory Committee (SAC)1 or another appropriate external review body, depending on the context and circumstances. They should also be compatible with FIND policies, its governance controls and practices.

FIND catalyses product development, evaluates opportunities, formulates positions, and accelerates access to tools and technologies that serve its mission. These activities are all based on scientifically validated or independently reviewed data, and objective2 standards. They are also conducted in compliance with FIND’s Code of Conduct and Ethics (the “CODE”) and its Statement of Recognition of Independence for Private Sector Partners, whose purpose is to ensure not only that FIND acts professionally and ethnically

---

1 Throughout this document, “SAC” refers to either the full SAC or a relevant sub-group.
2 Definition of “objective” for this document is: as defined by a stakeholder/expert group that includes parties other than FIND
at all times, but also that it is seen to act accordingly. FIND is subject to objective, independent and neutral review of its activities, including those involving private sector partners.

FIND acts transparently and without favouritism, free of any conflicts of interest to the best of its ability and scope of control. FIND provides indirect support to facilitate the development and implementation of fit-for-purpose diagnostic products for use in LMICs, through provision of access to specimen banks and clinical trial platforms, as well as disease, regulatory, technical and laboratory expertise. It also provides independent product evaluation data to the World Health Organization (WHO) and national disease control programmes. FIND occasionally also provides direct support to overcome bottlenecks or critical obstacles in the development of essential diagnostics projects in LMICs, for example, through limited co-funding with other partners.

This policy paper and the guidelines it contains clarify the criteria and bases on which FIND and its staff are expected to act at all times in order to ensure that its partnerships, projects and programmes are based on objective data, are free from undue influence and may be independently reviewed. This document further explains the principles and policies that FIND must apply for any substantive decisions regarding its partnering activities with industry or other private sector partners, when allocating resources to any of FIND’s four strategic goals or its programmes. These decisions should be available for external review to ensure FIND activities are free of any conflicts of interest or inappropriate private sector, political, organizational, social, and economic or other influences. FIND’s decisions and actions should be congruent at all times with its strategic goals and the appropriate standards.

FIND and its personnel (which includes its consultants), are expected to comply with a number of overarching principles that apply to everything that the organization does:

- Adhere to FIND’s CODE and comply with all local applicable laws, administrative requirements and regulations in countries where the organization works;
- Require all experts and private and public sector partners to accept FIND’s CODE (whenever possible), or a similar set of rules for avoiding any unethical behaviour or undeclared conflicts of interests; and
- Generate (whenever possible) effective, objective and meaningful ways of tracking, implementing and communicating progress, feedback and lessons learnt from each programme.

Further standards are presented in relation to each of FIND’s four strategic goals, as set forth below.

I. **Catalysing Development**

FIND’s primary objectives in catalysing development are to identify unmet diagnostic needs, find solutions for those needs and remove barriers to development of such solutions. This requires defining needs, scouting for and assessing new and complementary technologies, and providing access to FIND’s support platform for manufacturers, comprising its **Support for Success (S4S) programme** (e.g., know-how and expertise); match-making to broker or generate new development partnerships; **specimen collections**; and a clinical platform for feasibility studies. This work may include giving
access to research sites, reference materials, samples, biomarkers, new prototypes or experimental equipment. In all of these activities, FIND and its personnel (including consultants) are expected to:

1. Identify and use target product profiles (TPPs) that have been externally validated by WHO, public health bodies or an equivalent global consensus process, as a basis for decision-making;

2. Where TPPs do not exist, work closely with appropriate policy groups, researchers, country partners and implementers, in order to define a list of desired features and characteristics for any new diagnostic tools;

3. Set clear product requirement documents (PRDs) that are based on TPPs (whenever available) and are available for review by FIND’s SAC or another external review body;

4. Adhere to FIND’s technology review and selection process in order to facilitate access to FIND’s support platforms in a fair, reasonable and non-discriminatory manner, based on objective parameters and selection criteria that can be reviewed by the SAC or another external review body whenever needed;

5. Generate clear, standardized assessments to ensure equal opportunity access based on relevant TPPs and PRDs;

6. Ensure that the criteria used during the prioritization and selection of private sector partners, as well as the comparative advantages of each candidate (whenever several possible partners are identified), can be reviewed by the SAC or another external review body. This also applies to the work done by or produced through, working with any private sector partners that have been selected to assist in developing new TPP or PRD-based products;

7. Build and support open platforms and meet global access requirements such as open access technologies, intellectual property freedom-to-operate, publication of data, access to appropriate biological materials, all subject to FIND’s global access and intellectual property policies and any pre-existing contractual constraints. The goal is to ensure clear access rights whenever possible in order to facilitate broad adoption by manufacturers, research partners, suppliers and users for the development of affordable diagnostic products and services; and

8. Support a broad range of products, developers and manufacturers to meet identified needs in LMICs, especially those having high disease burden rates.

II. Guiding Use and Informing Policy

FIND’s primary objective in providing guidance and informing policy is to reduce the time from development to market of diagnostic products for particular diseases with unmet needs. FIND also seeks to facilitate a greater understanding of how, when and where to use diagnostic solutions, and provide access to objective and actionable data to inform and improve public policy guidelines and decision-making. This work includes: (i) supporting national and global processes for policy guidance and defining optimal quality assurance processes; (ii) providing openly-available clinical platforms to collect and
synthesize evidence and raw data to guide new diagnostic strategies; and (iii) promoting and facilitating data exchange between WHO, industry, governments, laboratories and healthcare practitioners to inform and improve decision-making. This involves working with partners to establish what data is needed, how to collect and store it, and how to make it accessible and retrievable in useful ways. It also involves leading or participating in clinical trials and ensuring that such trials are aligned with product, policy and regulatory needs. FIND’s work in this field does not involve acting as an industry lobbyist or seeking to advance the interests of any private sector entities or group of companies; it seeks only to support public health policies to the extent that they assist patients in LMICs. FIND’s primary goal here is to assist WHO and other public sector healthcare bodies in the design, collection, packaging, facilitation, and implementation of data-driven public policy guidelines, quality assurance processes and standard operating procedures. In all of these activities relating to this goal, FIND and its personnel are expected to:

1. Adhere to FIND’s relevant standard operating procedures (SOPs);
2. Prioritize products for trials using similar processes to those set out in Section I above;
3. Set appropriate end points (e.g., pre-trial, primary and/or secondary), consistent with validated TPPs;
4. Prioritize trial needs and design studies in agreement with normative bodies, a global consensus process, FIND’s SAC or another external body;
5. Use only clinical trial protocols that have been reviewed and accepted by the appropriate entity in any one country (WHO, appropriate national public health bodies, or their relevant ethics review boards);
6. Seek to establish and use standardized protocol templates that have been externally endorsed, ideally by WHO or relevant national public health bodies, if available, in order to ensure comparability and consistency of data for similar product categories by applying standardized templates and protocols;
7. Ensure independent statistical analysis of data;
8. Organize an independent data oversight committee or equivalent body;
9. Assist in the registration of trials with a national trial authorization body;
10. Only accept project-specific private sector funds for projects that are described in written agreements that can be independently reviewed by the SAC or another independent review body;
11. Declare on FIND’s website all substantial contributions (greater than US$ 5,000) from any private sector partners, whether received in cash or in kind (e.g., equipment, tests, or funded personnel);
12. Submit all trial data, whether or not relating to commercial products, for publication;
13. Make data used to reach the conclusions of a manuscript (e.g., related meta data and methods) available for review; and
14. Facilitate the ability of WHO and other public sector bodies to cross-check data and
III. **Accelerating Access**

FIND’s primary objectives in accelerating access to appropriate diagnostic products in LMICs are to: (i) support rapid translation of global policies into actionable country plans; (ii) enable quality assurance, approval, roll-out, adoption and use of proven diagnostic solutions; and (iii) support long-term and integrated diagnostic capabilities as a centrepiece of disease control. FIND achieves this by working closely with WHO, public sector entities, local governments and health ministries, medical, disease or patient-oriented associations, and externally validated private sector partners, who can assist in reaching these goals. This includes expanding and strengthening networks of high-quality diagnostic facilities, engaging with relevant healthcare providers, and providing timely and effective information to support public health programmes and enable patients to obtain diagnoses and appropriate care. In all of these activities, FIND and its personnel are expected to:

1. Prioritize products for implementation based on similar processes to those set forth in Section I above, as may be feasible and appropriate in each set of circumstances;
2. Restrict implementation support to products or classes of products that have been approved or supported by WHO (e.g., based on WHO policy guidelines or pre-qualification approvals) or, for HIV and hepatitis, have strict regulatory approval from one of the founding members/countries of the Global Harmonization Task Force;
3. Work in an impartial and objective manner with all private and public sector partners, based on evidence-based decision-making measures and any country-specific needs;
4. Work collaboratively with all stakeholders to facilitate meaningful uptake;
5. Coordinate activities with WHO and any local public health bodies;
6. Facilitate data tracking or post-market surveillance, and ensure transparent reporting and data sharing to the extent possible;
7. Provide assistance to countries to establish product registration policies, where requested, as well as data-driven testing policies and algorithms; and
8. Assist countries with their diagnostics capacity-building needs, including for the detection of new diseases or epidemics, and for new technologies, and assist them in working appropriately and transparently with private sector partners.

IV. **Shaping the Agenda**

FIND’s primary objectives in implementing this strategic goal are: (i) to champion and communicate the role of diagnostics as an essential part of good healthcare; and (ii) to shape the diagnostics landscape to foster investment and public sector willingness to support it. FIND seeks to do so by engaging in thought leadership, advocacy, and tracking of effective expenditure and allocation of resources to support viable and sustainable diagnostic solutions. In all of these activities relating to shaping the agenda, FIND and its
personnel are expected to:

1. Generate objective, statistically relevant and validated data whenever possible about the benefits of integrating diagnostics as part of a public healthcare strategy, such as cost effectiveness, accuracy, sensitivity, and patient-centred benefits of integrating diagnostic solutions in the prevention, reduction or elimination of diseases;

2. Promote evidence-based advocacy programmes, free of undue private sector influences or political interests;

3. Act as an independent and objective facilitator or advocate of evidence-based public healthcare programmes and policies, which align public and private sector interests with affordable, effective, sustainable, and patient-centred healthcare;

4. Measure and communicate empirical metrics for assessing the benefits and areas for improvement regarding the integration of diagnostics into national and global health agendas as identified by WHO and other public healthcare bodies; and

5. Create new opportunities for global healthcare funders, providers and public sector bodies to work together in designing optimal strategies for addressing unmet diagnostics needs in LMICs, especially those having high burden disease rates.

V. **Role of FIND’s Scientific Advisory Committee**

FIND’s SAC plays an important role as an independent body capable of reviewing all of FIND’s programmes and its activities with private sector partners. It ensures transparency and acts as an external committee of experts that can independently assess, monitor and provide feedback on FIND's efforts and decisions in implementing the policies and guidelines set forth in this document. The SAC reports directly to FIND’s **Board of Directors**, which has the ultimate authority and responsibility for approving all of FIND’s policies, strategic decisions and objectives. The Board consults regularly with the SAC, and considers all SAC recommendations. The SAC is capable of:

1. Providing independent, external and objective scientific input into all relevant activities related to FIND’s strategic goals;

2. Providing recommendations to the FIND Board directly, or through the Board’s Scientific Committee, on optimal technologies, partnering opportunities and disease portfolio strategies that are in line with FIND’s strategic objectives;

3. Assisting FIND in building and developing its strategy, and providing technical advice and support to FIND’s staff;

4. Advising FIND as a whole on all scientific matters, and supporting and reviewing the scientific management and progress of projects and partnerships; and

5. Providing expertise on diagnostics, relationship development and any other public health or scientific issue as may be requested by the Board, the Board’s Scientific Committee or FIND senior management.

All members of the SAC are required to comply with FIND’s **CODE**, and all relevant
documents relating to or defining SAC activities and responsibilities. SAC members are prominent experts in the field of healthcare, who contribute independent and complementary feedback based on their individual fields of expertise. With the exception of a maximum of three (3) SAC members who may be appointed by not-for-profit diagnostic industry associations, SAC members may not be private sector employees. SAC operations are regulated by FIND’s Board of Directors. All SAC members must inform the SAC Chair in writing of any consulting activities they may have with any private sector entities that may be relevant to FIND’s activities, and of any possible conflicts of interest relating to or arising out of their activities for FIND. In the event of any possible conflicts of interest, SAC members must recuse themselves from any votes on topics relating to such a project and from any involvement in such a project. The SAC is expected to review all private sector partnerships having a commercial value (whether in kind or in cash) in excess of US$ 200,000. This review function may also be done by other independent and external review bodies.

VI. Review of Ethical Issues

In keeping with FIND’s desire to ensure that all of its decisions and actions are in keeping with this document, all partners and stakeholders working with FIND are expected to report any behaviour not deemed to be in accordance with the provisions set forth in this document. Reports can be filed using the NAVEX EthicsPoint web-based reporting system that FIND has set up. This reporting system can be accessed via the “Ethics hotline” link on FIND’s website. Furthermore, in order to address any ethical issues that may result from the nature of its work with private sector partners or otherwise, FIND has access to external and independent medical and legal bioethicists, who can assist as circumstances warrant; an ethics review process may be advisable.

VII. Board Governance and Oversight

FIND’s implementation and compliance with this policy and the guidelines contained in it shall be overseen and regulated by the FIND Board of Directors. The Board shall periodically review how this policy is being applied, what private sector partnerships have been reviewed by the SAC or other external review body, and when such independent reviews are needed. The Board has the right to review and approve all private sector partnerships.